These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 24632719)
41. Drug therapy in cardiogenic shock. Ramdohr B Int J Clin Pharmacol; 1973 Apr; 7(2):118-26. PubMed ID: 4731279 [No Abstract] [Full Text] [Related]
42. Vasopressin in catecholamine-resistant septic and cardiogenic shock in very-low-birthweight infants. Meyer S; Löffler G; Polcher T; Gottschling S; Gortner L Acta Paediatr; 2006 Oct; 95(10):1309-12. PubMed ID: 16982509 [TBL] [Abstract][Full Text] [Related]
43. [Problem of cardiogenic shock therapy]. Chazov EI Kardiologiia; 1970 Jul; 10(7):5-12. PubMed ID: 4321603 [No Abstract] [Full Text] [Related]
44. Cardiogenic shock: Inotropes and vasopressors. Amado J; Gago P; Santos W; Mimoso J; de Jesus I Rev Port Cardiol; 2016 Dec; 35(12):681-695. PubMed ID: 27836218 [TBL] [Abstract][Full Text] [Related]
45. Cardiogenic shock. Recent advances in pharmacologic management. II. Kones RJ N Y State J Med; 1973 Aug; 73(15):1967-80. PubMed ID: 4354585 [No Abstract] [Full Text] [Related]
46. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. ; Alexander JH; Reynolds HR; Stebbins AL; Dzavik V; Harrington RA; Van de Werf F; Hochman JS JAMA; 2007 Apr; 297(15):1657-66. PubMed ID: 17387132 [TBL] [Abstract][Full Text] [Related]
47. Use of pressor agents in shock in myocardial infarction. GARAI O; SMITH KS Br Med J; 1958 Feb; 1(5065):247-51. PubMed ID: 13499913 [No Abstract] [Full Text] [Related]
48. [Use of nitroglycerin in the complex treatment of cardiogenic shock in patients with myocardial infarction]. Anshelevich IuV; Prutkin AF; Rubin AI; Orlova VP Kardiologiia; 1988 Apr; 28(4):87-9. PubMed ID: 3134569 [No Abstract] [Full Text] [Related]
52. [Prevention of ischemia associated with acute myocardial infarction]. Forrester JS; Chaterjee K Coeur Med Interne; 1974; 13(1):11-20. PubMed ID: 4849467 [No Abstract] [Full Text] [Related]
53. Treatment of cardiogenic shock. I. Cohen LS Md State Med J; 1972 Sep; 21(9):26-8. PubMed ID: 5054523 [No Abstract] [Full Text] [Related]
54. [Therapy of shock using vaso- and coagulation-active substances. Behavior of tissue oxygen in the dog kidney under the influence of vaso- and coagulation-active substances]. Lenz J; Hartel W; Linder MM; Muschaweck R Fortschr Med; 1972 Nov; 90(32):1199-201. PubMed ID: 4348841 [No Abstract] [Full Text] [Related]
55. How should I treat refractory cardiogenic shock in acute STEMI with multivessel occlusion? Achtchi A; Ibrahim AW; Rahman A; Tanveer Rab S; Noc M; Thiele H EuroIntervention; 2014 Dec; 10(8):1009-12. PubMed ID: 25244461 [No Abstract] [Full Text] [Related]
57. [Therapy of verapamil poisoning with noradrenaline and the phosphodiesterase inhibitor enoximone]. Link A; Hammer B; Weisgerber K; Böhm M Dtsch Med Wochenschr; 2002 Sep; 127(39):2006-8. PubMed ID: 12324881 [TBL] [Abstract][Full Text] [Related]
58. [Experimental and clinical experience in the use of vasoconstrictor and vasodilator agents in the intensive care and emergencies]. Grabarić B; Pantelić D Vojnosanit Pregl; 1973; 30(5):452-4. PubMed ID: 4772855 [No Abstract] [Full Text] [Related]
59. [Tako-tsubo syndrome: a case report]. Mardelle V; Ramiara P; Xeridat F; Peytel E Ann Fr Anesth Reanim; 2007 Feb; 26(2):181-2. PubMed ID: 17197154 [No Abstract] [Full Text] [Related]